

Acne Vulgaris Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/A3D3F215BBEEEN.html>

Date: May 2024

Pages: 134

Price: US\$ 6,499.00 (Single User License)

ID: A3D3F215BBEEEN

Abstracts

The 7 major acne vulgaris markets reached a value of US\$ 7.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 10.0 Billion by 2034, exhibiting a growth rate (CAGR) of 3.23% during 2024-2034.

The acne vulgaris market has been comprehensively analyzed in IMARC's new report titled "Acne Vulgaris Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acne vulgaris, commonly known as acne, refers to a chronic skin condition characterized by the formation of pimples, blackheads, and whiteheads. It appears mainly on the face but can also develop on the chest, back, and shoulders. Acne is caused by several factors, such as the overproduction of sebum by the sebaceous glands, accumulation of dead skin cells in the pores, and inflammation. The primary treatment for acne is the use of topical and/or oral medications. Topical treatments assist in unclogging the pores and promoting cell turnover. Certain oral medications, including antibiotics and hormonal therapy, are also prescribed to help control acne. While acne can be treated, it is important to note that it can be a chronic condition requiring ongoing management. Acne can be prevented with proper skincare routines such as keeping the skin clean, avoiding picking or squeezing pimples, and using non-comedogenic products. In addition, lifestyle changes, such as maintaining a healthy diet, can help inhibit the development of acne.

The increasing concerns among individuals about their physical appearance and the escalating awareness regarding skin-related issues like acne are primarily driving the global acne vulgaris market. In addition to this, the rising consumer preference for products infused with natural herbs and organic ingredients, such as aloe vera, honey, green tea, jojoba oil, etc., for treating acne is also propelling the market growth.

Moreover, several key players are making extensive investments in developing safer and more advanced treatment drugs with a better understanding of acne pathology. This, in turn, is further creating a positive outlook for the market. Apart from this, the widespread adoption of topical medications, such as benzoyl peroxide, salicylic acid, retinoids, etc., which assist in lowering the production of oil and preventing the clogging of pores, is acting as another significant growth-inducing factor. Additionally, the inflating number of online portals and websites commercializing acne treatment products coupled with the escalating demand for over-the-counter acne drugs is also augmenting the global market. Furthermore, the emerging popularity of light-based and laser therapies, such as blue light therapy and laser resurfacing, which target the bacteria that cause acne and reduce inflammation, is expected to drive the global acne vulgaris market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the acne vulgaris market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for acne vulgaris and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acne vulgaris market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the acne vulgaris market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the acne vulgaris market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current acne vulgaris marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the acne vulgaris market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the acne vulgaris market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the acne vulgaris market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of acne vulgaris across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of acne vulgaris by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of acne vulgaris by gender across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of acne vulgaris by type across the seven major markets?

How many patients are diagnosed (?2018-2034?) with acne vulgaris across the seven major markets?

What is the size of the acne vulgaris patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of acne vulgaris?

What will be the growth rate of patients across the seven major markets?

Acne Vulgaris: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for acne vulgaris drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acne vulgaris market?

What are the key regulatory events related to the acne vulgaris market?

What is the structure of clinical trial landscape by status related to the acne vulgaris market?

What is the structure of clinical trial landscape by phase related to the acne vulgaris market?

What is the structure of clinical trial landscape by route of administration related to the acne vulgaris market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 ACNE VULGARIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 ACNE VULGARIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 ACNE VULGARIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Epidemiology by Type (?2018-2034?)
 - 7.2.6 Diagnosed Cases (?2018-2034?)
 - 7.2.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Epidemiology by Type (?2018-2034?)
 - 7.3.6 Diagnosed Cases (?2018-2034?)
 - 7.3.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Epidemiology by Type (?2018-2034?)
 - 7.4.6 Diagnosed Cases (?2018-2034?)
 - 7.4.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Epidemiology by Type (?2018-2034?)
 - 7.5.6 Diagnosed Cases (?2018-2034?)
 - 7.5.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Epidemiology by Type (?2018-2034?)
 - 7.6.6 Diagnosed Cases (?2018-2034?)

- 7.6.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)
 - 7.7.4 Epidemiology by Gender (?2018-2034?)
 - 7.7.5 Epidemiology by Type (?2018-2034?)
 - 7.7.6 Diagnosed Cases (?2018-2034?)
 - 7.7.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Epidemiology by Type (?2018-2034?)
 - 7.8.6 Diagnosed Cases (?2018-2034?)
 - 7.8.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Epidemiology by Type (?2018-2034?)
 - 7.9.6 Diagnosed Cases (?2018-2034?)
 - 7.9.7 Patient Pool/Treated Cases (?2018-2034?)

8 ACNE VULGARIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 ACNE VULGARIS - UNMET NEEDS

10 ACNE VULGARIS - KEY ENDPOINTS OF TREATMENT

11 ACNE VULGARIS - MARKETED PRODUCTS

- 11.1 List of Acne Vulgaris Marketed Drugs Across the Top 7 Markets

- 11.1.1 Arazlo (Tazarotene) – Ortho Dermatologics
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
- 11.1.2 Aklief (Trifarotene) - Galderma/Mayne Pharma
 - 11.1.2.1 Drug Overview
 - 11.1.2.2 Mechanism of Action
 - 11.1.2.3 Regulatory Status
 - 11.1.2.4 Clinical Trial Results
 - 11.1.2.5 Sales Across Major Markets
- 11.1.3 Seysara (Sarecycline) - Almirall S.A./Paratek Pharmaceuticals
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Veltin (Clindamycin/tretinoin) - Stiefel Laboratories
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Winlevi (Clascoterone) - Cosmo Pharmaceuticals
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 ACNE VULGARIS - PIPELINE DRUGS

- 12.1 List of Acne Vulgaris Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 IDP-126 Gel - Bausch Health Companies
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action

- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status
- 12.1.2 SB204 - Novan
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status
- 12.1.3 B244 - AOBiome llc
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 BTX1503 - Botanix Pharmaceuticals
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 ASC-J9 - AndroScience Corporation
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. ACNE VULGARIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. ACNE VULGARIS – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 ACNE VULGARIS - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Acne Vulgaris - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Acne Vulgaris - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Acne Vulgaris - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Acne Vulgaris - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Acne Vulgaris - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Acne Vulgaris - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Acne Vulgaris - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Acne Vulgaris - Access and Reimbursement Overview

15.5 Market Scenario - France

15.5.1 Acne Vulgaris - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Acne Vulgaris - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Acne Vulgaris - Access and Reimbursement Overview

15.6 Market Scenario - United Kingdom

15.6.1 Acne Vulgaris - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

- 15.6.2 Acne Vulgaris - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 Acne Vulgaris - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Acne Vulgaris - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Acne Vulgaris - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Acne Vulgaris - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Acne Vulgaris - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Acne Vulgaris - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Acne Vulgaris - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Acne Vulgaris - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Acne Vulgaris - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Acne Vulgaris - Access and Reimbursement Overview

16 ACNE VULGARIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 ACNE VULGARIS MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 ACNE VULGARIS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Acne Vulgaris Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/A3D3F215BBEEEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A3D3F215BBEEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

